1. Home
  2. NTRB vs TENX Comparison

NTRB vs TENX Comparison

Compare NTRB & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nutriband Inc.

NTRB

Nutriband Inc.

HOLD

Current Price

$7.35

Market Cap

72.6M

Sector

Health Care

ML Signal

HOLD

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$1.90

Market Cap

71.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTRB
TENX
Founded
2016
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.6M
71.1M
IPO Year
2019
2001

Fundamental Metrics

Financial Performance
Metric
NTRB
TENX
Price
$7.35
$1.90
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
78.0K
4.5M
Earning Date
05-29-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,036,651.00
N/A
Revenue This Year
$30.17
N/A
Revenue Next Year
$3,394.36
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.80
$1.31
52 Week High
$8.63
$19.40

Technical Indicators

Market Signals
Indicator
NTRB
TENX
Relative Strength Index (RSI) 62.02 28.05
Support Level $3.53 $1.31
Resistance Level N/A $2.22
Average True Range (ATR) 0.80 0.12
MACD 0.01 0.36
Stochastic Oscillator 55.61 26.93

Price Performance

Historical Comparison
NTRB
TENX

About NTRB Nutriband Inc.

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: